99% up by HPLC Upad...

99% up by HPLC Upadacitinib 1310726-60-3

99% up by HPLC Upadacitinib 1310726-60-3

Min.Order / FOB Price:Get Latest Price

25 Kilogram

Negotiable

  • Min.Order :25 Kilogram
  • Purity: 99% up
  • Payment Terms : L/C,D/A,D/P,T/T,

Keywords

Upadacitinib 1310726-60-3 Upadacitinib 1310726-60-3

Quick Details

  • Appearance:White powder
  • Application:
  • PackAge:1kg/bag ;25kg/drum
  • ProductionCapacity:10|Metric Ton|Month
  • Storage:Dry place
  • Transportation:cool&dry place

Superiority:

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier . 

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Details:

Product name

Upadacitinib

CAS No.

1310726-60-3

Molecular Formula

C17H19F3N6O

Molecular Weight

380.3675696

Quality Standard

99% up by HPLC

Appearance

White to light brown powder

 

ITEMS

SPECIFICATION

RESULT

Appearance

White to light brown powder

Off-white powder

Water

1.8%-2.8%

0.50%

Residue on ignition

NMT 0.10%

0.03%

Heavy metal

NMT 10 ppm

Conforms

PSD

D90 NMT 50μm

13μm

 

 

Residual solvents

Alcohol: NMT 0.50%

0.014%

2-Methyltetrahydrofuran: NMT 0.50%

Not detected

Heptane: NMT 0.50%

0.0087%

Ethyl acetate: NMT 0.50%

0.33%

 

Related substances

The individual impurity : NMT 0.5%

0.06%

Total impurity: NMT 1.0%

0.07%

Enantiomer

NMT 0.15%

0.05%

Purity

NLT 99.0%

99.98%

Conclusion

The products complies with the enterprise standard

Function of Upadacitinib

Upadatinib is primarily indicated for patients with refractory, moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older who have not responded well to or are unsuitable for other systemic therapies (such as hormones or biologics). The launch of upadatinib extended-release tablets provides more options for the treatment of patients with atopic dermatitis. Upatinib works by blocking the activity of Janus kinases in the JAK-STAT signaling pathway. Proinflammatory cytokine stimulation causes inflammation in rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. The JAK-STAT signaling pathway is an intracellular pathway that plays a major role in the release of pro-inflammatory cytokines.

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View